褐藻多酚可改善肥胖者的DNA损伤
  • 纳入80名30-80岁、身体质量指数≥25的受试者参与一项随机对照实验,研究褐藻(多)酚提取物对DNA损伤,氧化应激和体内炎症的影响;
  • 褐藻多酚仅在肥胖参与者中显示出改善DNA损伤的作用;
  • C-反应蛋白(CRP)、抗氧化状态或炎性细胞因子无明显变化;
  • 鉴定出部分褐藻多酚可作为摄入褐藻后的潜在生物标记物,如邻苯三酚/间苯三酚-硫酸盐等;
  • 未来需要将参与者根据体重进行分组,进一步验证本实验研究结果。
主编推荐语
玉龙潭
流行病学证据表明,富含(多)酚的饮食对许多慢性疾病有益,而褐藻是(多)酚的丰富来源。本工作研究了褐藻(多)酚类物质在体内的生物活性和生物利用度,并确定了几种潜在的海藻摄入生物标志物。遗憾的是,本研究没有在体重方面对参与者进行分组,因此所得结论并不全面。未来需要将参与者根据体重进行分组,进一步验证本实验研究结果。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!

Impact of a (poly)phenol-rich extract from the brown algae Ascophyllum nodosum on DNA damage and antioxidant activity in an overweight or obese population: a randomized controlled trial

一种富含多酚的褐藻泡叶藻提取物对超重或肥胖人群DNA损伤及抗氧化的作用:一项随机对照试验

10.1093/ajcn/nqy147

2018-10-01, Article

Abstract & Authors:展开

Abstract:收起
Background: Epidemiologic evidence suggests that a diet rich in (poly)phenols has beneficial effects on many chronic diseases. Brown seaweed is a rich source of (poly)phenols.
Objective: The aim of this study was to investigate the bioavailability and effect of a brown seaweed (Ascophyllum nodosum) (poly)phenol extract on DNA damage, oxidative stress, and inflammation in vivo.
Design: A randomized, double-blind, placebo-controlled crossover trial was conducted in 80 participants aged 30-65 y with a body mass index (in kg/m2) ≥25. The participants consumed either a 400-mg capsule containing 100 mg seaweed (poly)phenol and 300 mg maltodextrin or a 400-mg maltodextrin placebo control capsule daily for an 8-wk period. Bioactivity was assessed with a panel of blood-based markers including lymphocyte DNA damage, plasma oxidant capacity, C-reactive protein (CRP), and inflammatory cytokines. To explore the bioavailability of seaweed phenolics, an untargeted metabolomics analysis of urine and plasma samples after seaweed consumption was determined by ultra-high-performance liquid chromatography-high-resolution mass spectrometry.
Results: Consumption of the seaweed (poly)phenols resulted in a modest decrease in DNA damage but only in a subset of the total population who were obese. There were no significant changes in CRP, antioxidant status, or inflammatory cytokines. We identified phlorotannin metabolites that are considered potential biomarkers of seaweed consumption including pyrogallol/phloroglucinol-sulfate, hydroxytrifurahol A-glucuronide, dioxinodehydroeckol-glucuronide, diphlorethol sulfates, C-O-C dimer of phloroglucinol sulfate, and C-O-C dimer of phloroglucinol.
Conclusions: To the best of our knowledge, this work represents the first comprehensive study investigating the bioactivity and bioavailability of seaweed (poly)phenolics in human participants. We identified several potential biomarkers of seaweed consumption. Intriguingly, the modest improvements in DNA damage were observed only in the obese subset of the total population. The subgroup analysis should be considered exploratory because it was not preplanned; therefore, it was not powered adequately. Elucidation of the biology underpinning this observation will require participant stratification according to weight in future studies. This trial was registered at clinicaltrials.gov as NCT02295878.

First Authors:
Francina R Baldrick

Correspondence Authors:
Chris I R Gill

All Authors:
Francina R Baldrick,Kevin McFadden,Maria Ibars,Chris Sung,Tanya Moffatt,Kate Megarry,Keith Thomas,Peter Mitchell,Julie M W Wallace,L Kirsty Pourshahidi,Nigel G Ternan,Giulia Corona,Jeremy Spencer,Parveen Yaqoob,Sarah Hotchkiss,Ross Campbell,José Manuel Moreno-Rojas,Francisco Julián Cuevas,Gema Pereira-Caro,Ian Rowland,Chris I R Gill

评论